[Comment] GLP-1 receptor agonists and cardiovascular risk in routine clinical practice

The management of hyperglycaemia in type 2 diabetes has become rather complex, with several glucose-lowering drugs now available that have shown different effects on cardiovascular outcomes, heart failure, and progression of chronic kidney disease. The recent consensus report1 from the American Diabetes Association and the European Association of the Study of Diabetes recommends the use of either sodium-glucose co-transporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists with proven cardiovascular benefit in patients with established cardiovascular disease.

Bekijk het originele bericht